Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $31.86 Consensus Target Price from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $31.8571.

A number of brokerages recently weighed in on TYRA. Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. Raymond James Financial began coverage on shares of Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Friday, August 22nd.

Institutional Investors Weigh In On Tyra Biosciences

Several large investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its holdings in shares of Tyra Biosciences by 41.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 97,736 shares of the company’s stock valued at $935,000 after purchasing an additional 28,786 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of Tyra Biosciences by 139.8% in the 2nd quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company’s stock valued at $5,583,000 after purchasing an additional 340,142 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Tyra Biosciences by 346.6% in the 2nd quarter. Bank of America Corp DE now owns 372,967 shares of the company’s stock valued at $3,569,000 after purchasing an additional 289,446 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth approximately $771,000. Finally, PDT Partners LLC purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth approximately $414,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Shares of TYRA opened at $13.52 on Thursday. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $29.60. The company has a 50-day moving average of $12.18 and a 200 day moving average of $10.56. The firm has a market capitalization of $720.58 million, a price-to-earnings ratio of -7.60 and a beta of 1.11.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. On average, equities analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.